Evaluate the Efficacy and Safety of the Digital Therapeutics Repeech for the Post-Stroke Dysarthria.

Inclusion Criteria:

1. Participants must be 19 years of age or older.

2. Participants must be neurologically stable post-stroke, as determined by a qualifiedphysician.

3. Participants must have dysarthria due to stroke, with a National Institutes ofHealth Stroke Scale (NIHSS) score 1 (mild) or 2 (moderate) for dysarthria.

4. participants must have a Korean-Modified Mini-Mental State Examination (K-MMSE)score of 26 or higher within 1 month prior to enrollment in the study.

5. Participants must have sufficient visual, auditory, langauge, and motor abilities tounderstand and follow the assessment procedures, as determined by the PrincipalInvestigator.

6. Participants must be able to use general-purpose digital equipment and comfortablewith using the digital therapeutics(DTx) platform for this study.

7. Participants must provide informed consent after receiving a thorough explanation ofthe study, including potential risks and benefits. They must understand and agree tofollow the study protocol.

Exclusion Criteria:

1. Participants with sigificant structural problems affecting the oral cavity andcervial region that would hinder accurate assessment.

2. Participants diagnosed with dementia, including Alzheimer's disease, Vasculardementia, Dementia due to Central Nervous System(CNS) infections (e.g., HIV,syphilis), Creutzfeldt-Jakob disease, Pick's disease, Huntington's disease,Parkinson's disease.

3. Participants currently receiving treatment for dementia within 3 months prior tostudy screening.

4. Participants who are unable to read or write in the language of the study.

5. Participants with severe mental health conditions including severe depression,schizophrenia, alcohol addicsion, drug dependence.

6. Participants with a severe langauge disorder, as determined by the physician(MD),that would significantly hinder their abiity to use digital therapeutics platform.

7. Participants deemed by the MD as unable to use general-purpose digital equipment.

8. Participants with additional medical or social concerns that, in the opinion of thePrindipal Investigator(PI), would make their participation in the clinical trialunsuitable or pose siginficant risks.

9. Participants who decline to participate in the study.